BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18613772)

  • 1. Idiotype vaccine strategies for improving outcomes in follicular lymphoma.
    Sinha R; Shenoy PJ; Flowers CR
    Expert Opin Biol Ther; 2008 Aug; 8(8):1213-23. PubMed ID: 18613772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-idiotype vaccines for human follicular lymphoma.
    Bendandi M
    Leukemia; 2000 Aug; 14(8):1333-9. PubMed ID: 10942225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H; Brody JD; Sinha R; Shenoy PJ; Flowers CR
    Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Bendandi M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine therapy for B-cell lymphomas: next-generation strategies.
    Neelapu SS; Kwak LW
    Hematology Am Soc Hematol Educ Program; 2007; ():243-9. PubMed ID: 18024636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma.
    Ai WZ; Tibshirani R; Taidi B; Czerwinski D; Levy R
    Blood; 2009 Jun; 113(23):5743-6. PubMed ID: 19346494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
    Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
    Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination strategies in follicular lymphoma.
    Kannan S; Neelapu SS
    Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy in follicular lymphoma.
    Veelken H
    Semin Cancer Biol; 2003 Jun; 13(3):241-7. PubMed ID: 12959355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraclonal variability of VH genes in follicular lymphoma patients who have received anti-idiotypic immunotherapy.
    Yáñez R; Barrios Y; Cabrera R; Díaz-Espada F
    J Immunother; 2006; 29(1):61-6. PubMed ID: 16365601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
    J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
    J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.